ClinicalTrials.Veeva

Menu

Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever

National Taiwan University logo

National Taiwan University

Status

Completed

Conditions

Neutropenic Fever

Study type

Observational

Funder types

Other

Identifiers

NCT01034059
200806051R

Details and patient eligibility

About

The soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) was an established biomarker useful for infection in non-neutropenic patients. In this study, we tested sTREM-1 in the patients with neutropenic fever. Pro-calcitonin (PCT) and C-reactive protein (CRP) were also measured. We planned to investigate and explore the role of sTREM-1 in early diagnosis of infection in patients with neutropenic fever.

Full description

Patients with hematological malignancies developed neutropenia after chemotherapy. We checked the serum level of sTREM-1 in patients with neutropenic fever. Those patients were classified to 2 groups: documented infection or low likelihood of infection. Their sTREM-1 level was measured and was compared with other biomarker such as CRP and procalcitonin. The value of sTREM-1 for diagnosis of infection in patients with neutropenic fever was thus evaluated.

Enrollment

75 patients

Sex

All

Ages

18 to 84 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • chemotherapy-related neutropenia (granulocytes < 0.5 × 109/l or leukocytes < 1 × 109/l) and fever (body temperature > 38.0°C over a 6 hour observation period or body temperature ≥ 38.5°C once.

Exclusion criteria

  • prolonged fever before presenting for admission,
  • antibiotics therapy in the past 72 hours,
  • more than two sites of infectious focus,
  • concomitant solid organ malignancy and blast in hemogram.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems